Mice overexpressing TRPC3 cDNA under the control of a modified human ACTA1 promoter show features of dystrophin-glycoprotein complex (DGC)-lacking dystrophic disease.
Jeffery D. Molkentin, Cincinnati Children's Hospital
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Inserted expressed sequence, Humanized sequence) |
TRPC (transient receptor potential canonical) genes have been implicated in the development of muscular dystrophy.
These transgenic animals overexpress human transient receptor potential canonical 3 (TRPC3) cDNA driven by a modified human ACTA1 (actin, alpha 1, skeletal muscle) promoter. A 6-fold increase in expression can be seen in skeletal muscle, but not other organs or tissues. Immunohistochemistry from the quadriceps confirms that the overexpressed protein is appropriately localized to the sarcolemma. An increase in calcium influx results in a phenotype similar to dystrophin-glycoprotein complex (DGC)-lacking dystrophic disease. Transgenic animals show profound wasting of all skeletal muscles examined at 2 months of age, as determined by direct measurement of muscle weights. Histological analysis of the muscles reveals increased central nucleation of fibers (due to degeneration/regeneration cycles), increased numbers of small myofibers, fibrosis, and infiltration of inflammatory cells. Disease progresses and by 6 months of age, fatty tissue replacement can be seen throughout muscle, along with increased fibrosis and greater variations in fiber area distributions with prominent macrophage infiltration. The heart is unaffected.
This transgene expresses full-length human TRPC3 cDNA under the control of a modified human ACTA1 skeletal alpha-actin promoter (likely incorporating bp -2000 to +239). The transgenic vector was introduced to FVB embryos. Resultant mice were maintained on an FVB genetic background by the donating laboratory.
Expressed Gene | TRPC3, transient receptor potential cation channel subfamily C member 3, human |
---|---|
Site of Expression |
Allele Name | transgene insertion 1, Jeffery Molkentin |
---|---|
Allele Type | Transgenic (Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | TRPC3 TG |
Gene Symbol and Name | Tg(ACTA1-TRPC3)1Jmol, transgene insertion 1, Jeffery Molkentin |
Gene Synonym(s) | |
Promoter | ACTA1, actin, alpha 1, skeletal muscle, human |
Expressed Gene | TRPC3, transient receptor potential cation channel subfamily C member 3, human |
Strain of Origin | FVB |
Chromosome | UN |
Molecular Note | A modified human ACTA1 skeletal alpha-actin promoter (-2000 to +239) was used to drive muscle-specific expression of full-length human TRPC3 cDNA. Line 1 was generated. |
Hemizygotes are viable and fertile. Homozygotes are viable, but the donating lab didn't use them in their breeding program.
When using the FVB-Tg(ACTA1*-TRPC3)1Jmol/J mouse strain in a publication, please cite the originating article(s) and include JAX stock #024052 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizygous or Non carrier for Tg(ACTA1*-TRPC3)1Jmol |
Frozen Mouse Embryo | FVB-Tg(ACTA1*-TRPC3)1Jmol/J Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | FVB-Tg(ACTA1*-TRPC3)1Jmol/J Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | FVB-Tg(ACTA1*-TRPC3)1Jmol/J Frozen Embryo | $3373.50 |
Frozen Mouse Embryo | FVB-Tg(ACTA1*-TRPC3)1Jmol/J Frozen Embryo | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.